Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Indinavir sulfate, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 8
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more

Conditions: G6PD Deficiency
Interventions: SD Biosensor STANDARD G6PD Test, Pointe Scientific Test Kit, HemoCue System; Diagnostic Test
Lead sponsor: PATH; Other
Eligibility: 18 Years to 65 Years
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Reading, Pennsylvania

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intestinal Failure-associated Liver Disease
Interventions: Not listed
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Kissimmee, Florida • Chicago, Illinois + 7 more

Conditions: Immunologic Deficiency Syndromes
Interventions: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV; Drug
Lead sponsor: FFF Enterprises; Industry
Eligibility: 3 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 5 more

Conditions: Endometrial Cancer
Interventions: ctDNA Testing, Blood draw, Surveys, Semi-structured interviews; Genetic · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Hiv, Chlamydia, Gonorrhea
Interventions: all2GETHER; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years to 34 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: R W Johnson Pharmaceutical Research Institute; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Heart Failure, Iron-deficiency
Interventions: Ferric Carboxymaltose, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,065 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Alexander City, Alabama • Auburn, Alabama • Mobile, Alabama + 157 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Interventions: cyclosporine, fludarabine, mycophenolate mofetil; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: stavudine extended-release, lamivudine, efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 46
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 43 more

Conditions: HIV Infections
Interventions: Kaletra® (lopinavir/ritonavir), Combivir® (lamivudine, zidovudine), Sustiva® (efavirenz); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions: CliniMACs device; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 22 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: VRX496-transduced autologous CD4 T cells; Genetic
Lead sponsor: VIRxSYS Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 2
States / cities: Norwalk, Connecticut • New York, New York

Conditions: Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions: Vitamin D3, Standard Vitamin D3 Supplementation; Dietary Supplement
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 1 Year to 25 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Vasopressin Deficiency
Interventions: Intranasal Oxytocin (IN-OXT), Placebo; Drug
Lead sponsor: Elizabeth Austen Lawson; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: HEART, Growing Minds; Behavioral
Lead sponsor: North Carolina State University; Other
Eligibility: 14 Years to 18 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Smoking, Smoking Cessation
Interventions: Wellness Intervention for Smokers with HIV; Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: X-Linked Hypophosphatemia
Interventions: KRN23; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Conditions: COVID-19, Lymphocytopenia
Interventions: CYT107, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Gainesville, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more

Search by objective public record fields.

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

Validation of a Diagnostic Test for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Anti-coagulated Blood

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

A Clinical Study of Intravenous Immunoglobulin

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Effectiveness of Relationship Education for Reducing HIV Incidence Among Men Who Have Sex With Men

Treatment Program for Anemia in AIDS Patients

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Pancreas Registry and High Risk Registry

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens

Effects of HIV on the Development and Function of Bone Marrow Cells

Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )